Amalgamated Bank grew its holdings in Blueprint Medicines (NASDAQ:BPMC) by 16.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,777 shares of the biotechnology company’s stock after purchasing an additional 837 shares during the quarter. Amalgamated Bank’s holdings in Blueprint Medicines were worth $436,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. Alyeska Investment Group L.P. acquired a new position in Blueprint Medicines in the third quarter worth $6,967,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Blueprint Medicines by 57.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 680 shares during the last quarter. California Public Employees Retirement System bought a new stake in shares of Blueprint Medicines during the second quarter worth $314,000. Virtus Fund Advisers LLC bought a new stake in shares of Blueprint Medicines during the fourth quarter worth $348,000. Finally, Swiss National Bank raised its position in shares of Blueprint Medicines by 26.4% during the fourth quarter. Swiss National Bank now owns 64,700 shares of the biotechnology company’s stock worth $4,879,000 after acquiring an additional 13,500 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.
In other Blueprint Medicines news, Director George Demetri sold 5,492 shares of the stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $100.09, for a total value of $549,694.28. Following the completion of the sale, the director now directly owns 10,231 shares in the company, valued at $1,024,020.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Nicholas Lydon sold 25,000 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $87.89, for a total value of $2,197,250.00. Following the completion of the sale, the director now owns 193,131 shares of the company’s stock, valued at $16,974,283.59. The disclosure for this sale can be found here. Insiders sold 89,567 shares of company stock valued at $7,651,106 in the last quarter. 3.40% of the stock is currently owned by corporate insiders.
A number of research firms have recently weighed in on BPMC. BidaskClub downgraded Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 29th. ValuEngine upgraded Blueprint Medicines from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Cowen restated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, February 21st. Zacks Investment Research upgraded Blueprint Medicines from a “hold” rating to a “buy” rating and set a $88.00 target price for the company in a research report on Monday, January 15th. Finally, Goldman Sachs boosted their target price on Blueprint Medicines from $82.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, December 11th. One investment analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company’s stock. Blueprint Medicines presently has an average rating of “Buy” and a consensus price target of $84.20.
NASDAQ BPMC traded down $2.36 on Friday, reaching $89.64. The company had a trading volume of 325,856 shares, compared to its average volume of 345,212. The company has a current ratio of 15.98, a quick ratio of 15.98 and a debt-to-equity ratio of 0.02. Blueprint Medicines has a 52 week low of $34.38 and a 52 week high of $109.00.
Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported ($1.23) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.16). The company had revenue of $1.63 million during the quarter, compared to the consensus estimate of $5.28 million. Blueprint Medicines had a negative net margin of 691.30% and a negative return on equity of 38.79%. The company’s revenue for the quarter was down 78.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.75) EPS. equities analysts predict that Blueprint Medicines will post -4.85 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Blueprint Medicines (NASDAQ:BPMC) Holdings Raised by Amalgamated Bank” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/blueprint-medicines-corp-bpmc-shares-bought-by-amalgamated-bank.html.
Blueprint Medicines Profile
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.